.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,022,330

« Back to Dashboard

Claims for Patent: 7,022,330

Title:Parenteral formulation for epothilone analogs
Abstract:A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.
Inventor(s): Bandyopadhyay; Rebanta (Portage, MI), Malloy; Timothy M. (Yardley, PA), Panaggio; Andrea (West Windsor, NJ), Raghavan; Krishnaswamy Srinivas (Cranbury, NJ), Varia; Sailesh Amilal (Princeton Junction, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/051,727
Patent Claims: 1. A process for formulating an epothilone analog represented by formula I: ##STR00007## and/or a pharmaceutically-acceptable salt, geometric, optical, or stereoisomer thereof, wherein: Q is ##STR00008## M is oxygen; each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.7 is, independently, selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl and heterocyclo, and wherein R.sup.1 and R.sup.2 are alkyl, they can be joined to form cycloalkyl; R.sup.6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, and heterocyclo; and any salts, solvates, or hydrates thereof, comprising the following steps: a) dissolving said epothilone analog in a mixture of at least about 50% by volume tertiary-butanol in water to form a solution; b) performing primary drying of said solution at a temperature of from about -10.degree. C. to about -40.degree. C. under vacuum of from about 50 millitorr to about 300 millitorr for from about 24 hours to about 96 hours to form a primary lyophilized product; and c) performing secondary drying of the primary lyophilized product at a temperature of from about 10.degree. C. to about 30.degree. C. under vacuum of from about 50 millitorr to about 300 millitorr for from about 24 hours to about 96 hours to provide a lyophilized product of the epothilone analog.

2. The process of claim 1 wherein said epothilone analog is represented by formula II: ##STR00009## and/or a pharmaceutically-acceptable salt, geometric, optical, or stereoisomer thereof.

3. The process of claim 1 wherein step a) comprises first, wetting said epothilone analog with a mixture of at least about 60% tertiary-butanol in water, and then adding sufficient water, or a mixture of tertiary-butanol and water, so that the resulting solution contains from about 2 mg/mL to about 30 mg/mL of said epothilone analog in a mixture of from about 50% to about 80% by volume tertiary-butanol in water.

4. The process of claim 2 wherein step a) comprises first, wetting said epothilone analog with a mixture of at least about 60% tertiary-butanol in water, and then adding sufficient water, or a mixture of tertiary-butanol and water, so that the resulting solution contains from about 2 mg/mL to about 30 mg/mL of said epothilone analog in a mixture of from about 50% to about 80% by volume tertiary-butanol in water.

5. The process of claim 3 wherein in step a) said epothilone analog is initially wetted with a mixture of from about 60% to about 95% by volume tertiary-butanol in water.

6. The process of claim 4 wherein in step a) said epothilone analog is initially wetted with a mixture of from about 60% to about 95% by volume tertiary-butanol in water.

7. The process of claim 2 wherein said primary drying in step b) is carried out at a temperature of from about -25.degree. C. to -40.degree. C. and a pressure of from about 200 to 300 millitorr.

8. The process of claim 2 wherein said secondary drying in step c) is carried out at a temperature of from about 25.degree. C. to 30.degree. C. and a pressure of from about 150 to 300 millitorr.

9. The process of claim 1, further comprising the step of: d) packaging said lyophilized product of the epothilone analog in a first vial and packaging in a second vial a sufficient quantity of a mixture comprising at least one suitable nonionic surfactant and at least one dehydrated alcohol to effect reconstitution of the lyophilized product.

10. The process of claim 9 wherein the mixture comprises about equal parts by volume of anhydrous ethanol and the at least one nonionic surfactant.

11. The process of claim 9 wherein said epothilone analog is: ##STR00010## and/or a pharmaceutically-acceptable salt, geometric, optical, or stereoisomer thereof.

12. The process of claim 9 wherein said surfactant is polyethoxylated castor oil.

13. The process of claim 11 wherein said surfactant is polyethoxylated castor oil.

14. The process of claim 9 wherein said second vial contains an amount of said mixture sufficient to form a solution of from about 2 mg/mL to about 4 mg/mL of said epothilone analog therein.

15. A process for formulating an epothilone analog having the formula: ##STR00011## and/or a pharmaceutically-acceptable salt, geometric, optical, or stereoisomer thereof, comprising: a) dissolving said epothilone analog in a mixture of tertiary butanol and water to form a solution, wherein the mixture comprises at least about 50% by volume tertiary butanol; b) performing primary drying of said solution at a temperature, chamber pressure and period of time sufficient to form a primary lyophilized product; and c) performing secondary drying of the primary lyophilized product at a temperature, chamber pressure and for a period of time sufficient to form a lyophilized product of the epothilone analog.

16. The process of claim 15, wherein said step a) of dissolving said epothilone analog is carried out at a temperature below ambient temperature.

17. The process of claim 15, wherein said step a) of dissolving said epothilone analog comprises first, wetting said epothilone analog with a mixture of at least about 60% by volume tertiary-butanol in water, and then adding sufficient water, or a mixture of tertiary-butanol and water, so that the resulting solution contains at least about 50% by volume tertiary-butanol in water.

18. The process of claim 15, wherein said step a) of dissolving said epothilone analog is carried out in the absence of an excipient.

19. The process of claim 15 wherein said primary drying in step b) is carried out at a temperature of from about -10.degree. C. to -40.degree. C. and at a chamber pressure of from about 50 to 300 millitorr for a period of up to about 96 hours.

20. The process of claim 19 wherein said secondary drying in step c) is carried out at a temperature of from about 10.degree. C. to 300.degree. C. and at a chamber pressure of from about 150 to 300 millitorr for a period of up to about 96 hours.

21. The process of claim 15, further comprising the step of: d) packaging said lyophilized product of the epothilone analog in a first vial and packaging in a second vial a sufficient quantity of a solvent mixture to effect reconstitution of the epothilone analog, wherein the solvent mixture of the second vial comprises at least one suitable nonionic surfactant and at least one anhydrous alcohol.

22. A process for formulating an epothilone analog represented by formula II: ##STR00012## and/or a pharmaceutically-acceptable salt, geometric, optical, or stereoisomer thereof, comprising: a) dissolving said epothilone analog to form a solution, comprising first, wetting said epothilone analog with a mixture of at least about 60% by volume tertiary-butanol in water, and then adding sufficient water, or a mixture of tertiary-butanol and water, so that the resulting solution contains at least about 50% by volume tertiary-butanol in water, wherein said step of dissolving is carried out at a temperature below ambient temperature; b) performing primary drying of said solution at a temperature, chamber pressure and for a period of time sufficient to form a primary lyophilized product; and c) performing secondary drying of the primary lyophilized product at temperature, chamber pressure and for a period of time sufficient to form a lyophilized product of the epothilone analog.

23. The process of claim 22 wherein, step b) of primary drying of said solution is performed at a temperature of about -10.degree. C. to about -40.degree. C. under vacuum of from about 50 millitorr to about 300 millitorr for from about 24 hours to about 96 hours; and step c) of secondary drying is performed at a temperature of from about 10.degree. C. to about 30.degree. under vacuum of from about 50 millitorr to about 300 millitorr for from about 24 hours to about 96 hours to provide a lyophilized product of the epothilone analog.

24. The process of claim 23 wherein, step a) of dissolving said epothilone analog is carried out at a temperature of from about -5.degree. C. to about 15.degree. C.

25. The process of claim 24 wherein, step a) of dissolving said epothilone analog is carried out in the absence of an excipient.

26. The process of claim 24, further comprising the step of: d) packaging said lyophilized product of the epothilone analog in a first vial and packaging in a second vial a sufficient quantity of a solution to effect reconstitution of the lyophilized epothilone analog, wherein the solution of the second vial comprises about equal amounts of at least one suitable nonionic surfactant and at least one anhydrous alcohol.

27. A pharmaceutical preparation comprising a lyophilized epothilone analog prepared according to claim 1.

28. A pharmaceutical preparation comprising a lyophilized epothilone analog prepared according to claim 2.

29. A pharmaceutical preparation comprising a lyophilized epothilone analog prepared according to claim 15.

30. A pharmaceutical preparation comprising a lyophilized epothilone analog prepared according to claim 20.

31. A pharmaceutical preparation comprising a lyophilized epothilone analog prepared according to claim 24.

32. A pharmaceutical product comprising at least a first and a second vial wherein the first vial contains a lyophilized epothilone analog prepared according to claim 2, and the second vial contains a sufficient quantity of a solution to effect reconstitution of the lyophilized epothilone analog, wherein the solution of the second vial comprises about equal amounts of at least one suitable nonionic surfactant and at least one anhydrous alcohol.

33. A method of treating a patient comprising, mixing the contents of the first and second vials of the pharmaceutical product of claim 32 to provide an epothilone analog solution, diluting the epothilone analog solution with a quantitiy of a suitable parenteral diluent to prepare an intravenous formulation, and administering the intravenous formulation to the patient.

34. A pharmaceutical product comprising at least a first and a second vial wherein the first vial contains a lyophilized epothilone analog prepared according to claim 15, and the second vial contains a sufficient quantity of a solution to effect reconstitution of the lyophilized epothilone analog, wherein the solution of the second vial comprises about equal amounts of at least one suitable nonionic surfactant and at least one anhydrous alcohol.

35. A method of treating a patient comprising, mixing the contents of the first and second vials of the pharmaceutical product of claim 34 to provide an epothilone solution, diluting the epothilone solution with a quantitiy of a suitable parenteral diluent to prepare an intravenous formulation, and administering the intravenous formulation to the patient.

36. The process of claim 15, wherein said step a) of dissolving said epothilone analog is carried out at a temperature in the range of from about 5.degree. C. to about 15.degree. C.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc